Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer - PubMed (original) (raw)
Review
doi: 10.1038/nrc1779.
Affiliations
- PMID: 16397526
- DOI: 10.1038/nrc1779
Free article
Review
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Saverio Minucci et al. Nat Rev Cancer. 2006 Jan.
Free article
Abstract
Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.
Similar articles
- Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA, Santoro F, Minucci S. Botrugno OA, et al. Cancer Lett. 2009 Aug 8;280(2):134-44. doi: 10.1016/j.canlet.2009.02.027. Epub 2009 Apr 2. Cancer Lett. 2009. PMID: 19345000 Review. - Histone deacetylase inhibitors for epigenetic therapy of cancer.
Monneret C. Monneret C. Anticancer Drugs. 2007 Apr;18(4):363-70. doi: 10.1097/CAD.0b013e328012a5db. Anticancer Drugs. 2007. PMID: 17351388 Review. - Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS, Parmigiani RB, Marks PA. Xu WS, et al. Oncogene. 2007 Aug 13;26(37):5541-52. doi: 10.1038/sj.onc.1210620. Oncogene. 2007. PMID: 17694093 Review. - Targeting histone deacetylase in cancer therapy.
Lin HY, Chen CS, Lin SP, Weng JR, Chen CS. Lin HY, et al. Med Res Rev. 2006 Jul;26(4):397-413. doi: 10.1002/med.20056. Med Res Rev. 2006. PMID: 16450343 Review. - Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A, Altucci L. Mai A, et al. Int J Biochem Cell Biol. 2009 Jan;41(1):199-213. doi: 10.1016/j.biocel.2008.08.020. Epub 2008 Aug 22. Int J Biochem Cell Biol. 2009. PMID: 18790076 Review.
Cited by
- CUL4B Promotes Breast Carcinogenesis by Coordinating with Transcriptional Repressor Complexes in Response to Hypoxia Signaling Pathway.
Huang W, Zhang J, Huo M, Gao J, Yang T, Yin X, Wang P, Leng S, Feng D, Chen Y, Yang Y, Wang Y. Huang W, et al. Adv Sci (Weinh). 2021 Mar 16;8(10):2001515. doi: 10.1002/advs.202001515. eCollection 2021 May. Adv Sci (Weinh). 2021. PMID: 34026424 Free PMC article. - Probing arginine side-chains and their dynamics with carbon-detected NMR spectroscopy: application to the 42 kDa human histone deacetylase 8 at high pH.
Werbeck ND, Kirkpatrick J, Hansen DF. Werbeck ND, et al. Angew Chem Int Ed Engl. 2013 Mar 11;52(11):3145-7. doi: 10.1002/anie.201209385. Epub 2013 Feb 10. Angew Chem Int Ed Engl. 2013. PMID: 23401322 Free PMC article. No abstract available. - HDAC inhibitor-induced drug resistance involving ATP-binding cassette transporters (Review).
Ni X, Li L, Pan G. Ni X, et al. Oncol Lett. 2015 Feb;9(2):515-521. doi: 10.3892/ol.2014.2714. Epub 2014 Nov 19. Oncol Lett. 2015. PMID: 25624882 Free PMC article. - HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure.
Stypula-Cyrus Y, Damania D, Kunte DP, Cruz MD, Subramanian H, Roy HK, Backman V. Stypula-Cyrus Y, et al. PLoS One. 2013 May 28;8(5):e64600. doi: 10.1371/journal.pone.0064600. Print 2013. PLoS One. 2013. PMID: 23724067 Free PMC article. - Sodium valproate affects the expression of p16INK4a and p21WAFI/Cip1 cyclin‑dependent kinase inhibitors in HeLa cells.
Rocha MA, Cardoso AL, Martins C, Mello MLS. Rocha MA, et al. Oncol Lett. 2024 Jul 11;28(3):432. doi: 10.3892/ol.2024.14563. eCollection 2024 Sep. Oncol Lett. 2024. PMID: 39049983 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources